



Letter

Development of a biosensor assessing SARS-CoV-2 main protease proteolytic activity in living cells for antiviral drugs screening

Yuan Zhang^{a,1}, Chunjie Li^{a,d,1}, Xianliang Ke^a, Dan Luo^b, Yan Liu^a, Quanjiao Chen^a, Hanzhong Wang^a, Xiaohui Song^{c,*}, Zhenhua Zheng^{a,*}^a Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China^b Department of Gastroenterology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, 430015, China^c Department of Obstetrics, Wuhan Children's Hospital, Wuhan Maternal and Child Healthcare Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, 430015, China^d University of the Chinese Academy of Sciences, Beijing, 100049, China

Dear Editor,

The Coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The genome of this virus encodes two overlapping polyproteins, pp1a and pp1ab (Wu et al., 2020; Zhou et al., 2020). The functional polypeptides are released from those two polyproteins by extensive proteolytic events, mostly mediated by main protease (M^{pro}, also known as 3CL^{pro}). It cleaves the polyproteins at no less than 11 conserved sites to produce non-structure proteins (Nsps) (Wu et al., 2020), and no human protease has been found to share similar cleavage specificity (Wu et al., 2020). Since these cleavage events play an essential role in viral replication and pathogenesis, M^{pro} is considered as one of the most attractive targets for drugs development to combat the ongoing COVID-19 pandemic (Pillaiyar et al., 2016).

Gaussia Luciferase (GLuc) is a naturally secreted luciferase (Luc) from the deep sea copepod *Gaussia princeps* (Bowling and Case, 1991). It is an ideal genetic reporter because it offers greatly increased bioluminescence than other commonly used Lucs (Bartok et al., 2013). It was reported that the fusion of mouse pro-interleukin (IL)-1 β on the N-terminal of GLuc can inhibit its catalytic activity because pro-IL-1 β can lead protein aggregates (Bartok et al., 2013).

To date, no M^{pro} inhibitor has been approved for SARS-CoV-2. In this study, we present a transgene-encoded biosensor that monitors the cleavage activity of SARS-CoV-2 M^{pro} in living cells. As shown in Fig. 1A, a fusion protein constructed of mouse pro-IL-1 β and GLuc lacking secretion signal (i-GLuc) was generated as the negative control. A canonical M^{pro} cleavage site AVLQ↓SGFR was inserted into i-GLuc at different positions to generate three biosensors to monitor M^{pro} activity. Theoretically, pro-IL-1 β renders GLuc enzyme inactive in these

biosensors, but M^{pro} can cleave the biosensors, leading to protein monomerization and GLuc activation.

Western blot assay was performed in HEK293T cell to test the cleavage of biosensors by M^{pro} (Supplementary Material). As expected, when co-expressed with SARS-CoV-2 M^{pro}, no cleaved band of i-GLuc appeared, but cleaved Flag-tagged bands of three biosensors were observed (Fig. 1B), indicating M^{pro} processed the cleavage site within the biosensors effectively and specifically.

Luciferase assay was performed to validate the efficiency of biosensors. As shown in Fig. 1C, i-GLuc generated similar bioluminescence in HEK293T cell with or without M^{pro}. In contrast, when M^{pro} was co-expressed with biosensors, an obvious increase of the GLuc signal occurred. The signal-to-background ratios (SBRs) of three biosensors were 3.97, 13.10, and 11.60, indicating M^{pro}-mediated cleavage activated GLuc activity in biosensors. Since the i-MS-GLuc2 construct presented the highest SBR, it was used for the succeeding experiments. The Linear range of i-MS-GLuc2 was presented in Supplementary Figure S1.

Five reported potential M^{pro} inhibitors discovered by structure-based virtual or non-cell-based screening, including disulfiram (Jin et al., 2020), GC376, anacardic acid, GW5074, and walrycin B (Jin et al., 2020; Zhu et al., 2020), were analyzed by the biosensor co-expressed with SARS-CoV-2 M^{pro}. GC376 and walrycin B obviously decreased the bioluminescence of the M^{pro}-active biosensor (Fig. 1D). Further, we tested the effects of these two drugs on the negative control iGLuc. GC376 had no effect on the signal of iGLuc, but the iGLuc signal decreased as the concentration of walrycin B increased (Fig. 1E and F). It may be caused by the cytotoxicity of walrycin B. Cell Counting Kit-8 (CCK-8) assay was performed on HEK293T cells to confirm this hypothesis (Supplementary Figure S2). GC376 showed no cytotoxicity on HEK293T cells even at a

* Corresponding authors.

E-mail addresses: songxiaohui@zgwhfe.com (X. Song), zhengzh@wh.iov.cn (Z. Zheng).¹ Yuan Zhang and Chunjie Li have contributed equally to this work.




Fig. 1. Development of a biosensor assessing SARS-CoV-2 main protease activity in living cells for antiviral drugs screening. **A** Construction of i-GLuc and three biosensors. **B** Cleavage efficacy of SARS-CoV-2 M^{pro} on i-GLuc and biosensors detected by Western blot (WB). HEK293T cells were transfected with pHA- M^{pro} and p-i-GLuc or biosensors expression plasmids. Cells were lysed and subjected to WB at 24 hours post-transfection. **C** Cleavage efficacy of SARS-CoV-2 M^{pro} on i-GLuc and biosensors detected by luciferase assay. HEK293T cells were co-transfected with pHA- M^{pro} /empty vector (EV) and p-i-GLuc or biosensors expression plasmids. Cells were lysed and subjected to luciferase assay at 24 hours post-transfection. **D** The inhibition of five potential inhibitors against M^{pro} detected by the biosensor. HEK293T cells were transfected with pHA- M^{pro} and p-i-MS-GLuc2-Flag. At 4 hours post-transfection, cells were treated with DMSO, anacardic acid, disulfiram, GC376, GW5074 and walrycin B respectively, drug concentration = 20 $\mu\text{mol/L}$. **E-F** The effect of walrycin B and GC376 on negative control i-GLuc. HEK293T cells were transfected with pHA- M^{pro} and p-i-GLuc-Flag. At 4 hours post-transfection, cells were treated with walrycin B or GC376 at different concentration. **G** The cleavage effect of SARS-CoV-2 M^{pro} in VERO-E6-i-MS-GL2 cells detected by luciferase assays. Cells were transfected with empty vector (EV) or pHA- M^{pro} . At 24 hours post-transfection, cells were lysed and subjected to luciferase assay. **H** The correlation between the SARS-CoV-2 viral titer and luciferase activity in VERO-E6-i-MS-GLuc2 cells. Cells were infected with SARS-CoV-2 at MOI of 0–0.1. At 24 hours post-infection, cells were lysed and subjected to luciferase assay. **I** The dose-dependent anti-viral effect of GC376 in VERO-E6-i-MS-GLuc2 cells. Cells were infected with SARS-CoV-2 at an MOI of 0.1. At one hour post-infection, cells were treated with GC376 at 0, 2, and 20 $\mu\text{mol/L}$. Luciferase activity was tested at 24 hours post-infection. These results are presented as the means $\pm$ SD of triplicate measurements. Error bars show the standard deviation of three experiments. Student's *t*-test; ns, non-significant, * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.

high concentration of 20 $\mu\text{mol/L}$, while walrycin B showed obvious cytotoxicity at the concentration of 0.1 $\mu\text{mol/L}$.

To facilitate anti-viral drugs screening, two reporter cell lines Vero E6-i-MS-GL2 and Vero-i-MS-GL2 that stably express i-MS-GLuc2 biosensor and sensitive to SARS-CoV-2 were constructed. Overexpressed M^{pro} led to GLuc signal increased in both reporter cell lines as predicted (Fig. 1G and Supplementary Figure S3). To test the sensitivity of the reporter cell line against live virus, Vero E6-i-MS-GL2 was infected with SARS-CoV-2 at MOI of 0.0005–0.1. Fig. 1H shows a good correlation between viral titer and GLuc signal. Cells infected with virus at an MOI of 0.1 showed significant GLuc signal increase and evident cytopathic effects (CPE), but no cell detachment. Thus, we used this MOI in the drug inhibition experiments.

GC376 was used to validate the cell line-based antiviral drugs screening system. We detected the inhibitory effects of GC376 at different concentrations on SARS-CoV-2 in reporter cell line via

luciferase assay. As expected, the GLuc signal decreased as drug concentration increased from 0 $\mu\text{mol/L}$ to 20 $\mu\text{mol/L}$ (Fig. 1I), indicating the inhibition of virus by this drug. Thus, this reporter cell line could be applied as an antiviral drugs screening tool.

In this study, we presented a transgene-encoded GLuc biosensor and a cell-based antiviral drugs screening system that allowed the monitoring of SARS-CoV-2 M^{pro} activity in living cells instead of *in vitro* solutions. Except for biosensor based on GLuc, some other fluorescent reporters to detect SARS-CoV-2 M^{pro} activity were developed (Froggatt et al., 2020; Rawson et al., 2021). All of these systems are suitable for high-throughput assay. EGFP is visible and luciferase is more sensitive and quantifiable (Supplementary Table S1). Compared with other enzymatic activity assays, GLuc assay is highly sensitive, quantifiable, and easy to operate, suitable for high-throughput screening. However, the effect of drugs on negative control i-GLuc should be tested, and internal control should be involved to avoid uncertain results caused by

some interference factors, such as drug cytotoxicity. In addition, our system has the potential to be applied in animal models because GLuc can be used in small animals as a marker. Therefore, it should be extremely useful for studying viral protease and screening novel anti-viral agents.

Footnotes

This work was supported by the National Natural Science Foundation of China (Grant No. 81871665). The SARS-CoV-2 infection experiments were performed at National Biosafety Laboratory, Wuhan, Chinese Academy of Sciences, and we thank Tao Du, Jin Xiong and Lun Wang from the laboratory for their critical support. The authors declare that they have no conflict of interest. This article does not contain any studies with human or animal subjects performed by any of the authors.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.virs.2022.04.002>.

References

- Bartok, E., Bauernfeind, F., Khaminets, M.G., Jakobs, C., Monks, B., Fitzgerald, K.A., Latz, E., Hornung, V., 2013. iGLuc: a luciferase-based inflammasome and protease activity reporter. *Nat. Methods* 10, 147–154.
- Bowlby, M.R., Case, J.F., 1991. Flash kinetics and spatial patterns of bioluminescence in the copepod *gaussia-princeps*. *Mar. Biol.* 110, 329–336.
- Froggatt, H.M., Heaton, B.E., Heaton, N.S., 2020. Development of a fluorescence-based, high-throughput SARS-CoV-2 3CL(pro) reporter assay. *J. Virol.* 94, e01265, 20.
- Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., Duan, Y., Yu, J., Wang, L., Yang, K., Liu, F., Jiang, R., Yang, X., You, T., Liu, X., Yang, X., Bai, F., Liu, H., Liu, X., Guddat, L.W., Xu, W., Xiao, G., Qin, C., Shi, Z., Jiang, H., Rao, Z., Yang, H., 2020. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. *Nature* 582, 289–293.
- Pillaiyar, T., Manickam, M., Namasivayam, V., Hayashi, Y., Jung, S.H., 2016. An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy. *J. Med. Chem.* 59, 6595–6628.
- Rawson, J.M.O., Duchon, A., Nikolaitchik, O.A., Pathak, V.K., Hu, W.S., 2021. Development of a cell-based luciferase complementation assay for identification of SARS-CoV-2 3CL(pro) inhibitors. *Viruses* 13, 173.
- Wu, F., Zhao, S., Yu, B., Chen, Y.M., Wang, W., Song, Z.G., Hu, Y., Tao, Z.W., Tian, J.H., Pei, Y.Y., Yuan, M.L., Zhang, Y.L., Dai, F.H., Liu, Y., Wang, Q.M., Zheng, J.J., Xu, L., Holmes, E.C., Zhang, Y.Z., 2020. A new coronavirus associated with human respiratory disease in China. *Nature* 579, 265–269.
- Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L., Chen, H.D., Chen, J., Luo, Y., Guo, H., Jiang, R.D., Liu, M.Q., Chen, Y., Shen, X.R., Wang, X., Zheng, X.S., Zhao, K., Chen, Q.J., Deng, F., Liu, L.L., Yan, B., Zhan, F.X., Wang, Y.Y., Xiao, G.F., Shi, Z.L., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 579, 270–273.
- Zhu, W., Xu, M., Chen, C.Z., Guo, H., Shen, M., Hu, X., Shinn, P., Klumpp-Thomas, C., Michael, S.G., Zheng, W., 2020. Identification of SARS-CoV-2 3CL protease inhibitors by a quantitative high-throughput screening. *ACS Pharmacol Transl Sci* 3, 1008–1016.